Tag:

Infectious Diseases

Latest Headlines

Latest Headlines

Ebola news: GSK, Emergent start Phase I trial; Bavarian Nordic scores €50M for vaccine development

In a big week for Ebola vaccines, Emergent Biosciences and GlaxoSmithKline have begun a Phase I trial of their candidates, while Bavarian Nordic received €50 million ($56 million) in loans from the European Investment Bank that go in part toward its programs in Ebola and infectious diseases.

NIH-backed West Nile candidate enters PhI trials at Duke

Despite years of efforts from academia and the industry, including Merck, no FDA-approved West Nile virus vaccine exists. Scientists from Oregon Health & Science University are looking to change that.

UPDATED: Analyst: Genocea's genital herpes vaccine better positioned than Agenus' to enter market

Genocea Biosciences' GEN-003 vaccine is well-positioned to compete in the genital herpes treatment market. It's in a better position, in fact, than Agenus' HerpV, according to a GlobalData analyst.

City of Hope, Fortress Biotech form new company to ward off CMV

Cytomegalovirus (CMV) presents no symptoms in most healthy people, but it can be life-threatening in people with weakened or underdeveloped immune systems. So City of Hope and Fortress Biotech have joined the race to produce vaccines to control CMV infections.

As California measles cases mounted, so did Merck measles vaccine sales

The California measles outbreak may have just given new meaning to the phrase "scaring up some business." As news of the outbreak spread, health officials urged parents to vaccinate their children. And as more and more cases were reported--escalating from 7 cases to more than 100 in just one month--sales of Merck's M-M-R II vaccine shot up too,

Final trial results show GSK malaria vaccine's efficacy wanes over time

In a Phase III trial involving 15,000 children in Africa, early results showed that children who received three doses of GlaxoSmithKline's candidate malaria vaccine were half as likely to contract malaria infection in the year after vaccination. But results reported Friday in The Lancet showed a significant decline in the level of protection after four years.

PaxVax expands commercial network for typhoid vaccine

PaxVax's typhoid vaccine, Vivotif, is licensed for sale in 27 countries. But the Redwood, CA-based company is looking to expand its presence, announcing on Wednesday a series of commercial partnerships and distribution agreements to ensure availability of Vivotif in Australia and Europe.

Mymetics-led consortium scores €8.4M to develop thermostable vaccines

The need for cold-chain transportation has been a prominent barrier in making vaccines available to developing countries. A consortium led by Mymetics' Dutch subsidiary has just received €8.4 million to change that.

Sinovac to trial jab with potential to disrupt Pfizer in China

Chinese vaccines producer Sinovac laid out big R&D plans this week to test multiple candidates--one of which has the potential to challenge Big Pharma's standing in the country.

Study: Serum Institute's powdered measles vaccine inferior to traditional jab

In December, Serum Institute of India reported victory in a Phase I trial of its powdered measles vaccine. But it may have to go back to the drawing board as results from a noninferiority trial reported Thursday showed that the powdered candidate was not as effective as the traditional injected vaccine.